Skip to main content
Sign In
 

Hematology, Oncology & Bone Marrow Transplantation - Research Funding


 

(listed alphabetically by Principal Investigator or by Section faculty member involved)

An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999 - present

An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999 - present

A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated Dose Micafungin as Antifungal Prophylaxis in Children and Adolescents Undergoing Stem Cell Transplantation
Principal Investigator: Edythe A. Albano, MD
Source: Astellas Pharma
Amount: Per case reimbursement
Term: 2008 - 2009

A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003 - present

Development of a Laboratory Kit for Neutrophil Priming
Principal Investigator: Daniel R. Ambruso, MD
Source: Colorado Bioscience Technology Grant, UCD
Amount: $156,000/yr
Term: 2007 - 2008

Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer, Inc.
Amount: $2,000/yr
Term: 1997 - 2006

Minor Antigen-Matched Red Cell Transfusion for Sickle Cell Disease
Principal Investigator: Daniel R. Ambruso, MD
Investigator: Rachelle Nuss, MD
Source: Bonfils Blood Center
Amount: $12,000/yr
Term: 2001 - present

Neoantigen and Biological Response Modifier Formation by the Mirasol Pathogen Reduction System for Platelet Concentrates
Principal Investigator: Daniel R. Ambruso, MD
Source: Navigant
Amount: $25,000/yr
Term: 2007 - 2008

Program in Pediatric Transfusion Medicine
Principal Investigator: Daniel R. Ambruso, MD
Source: NHLBI, NIH - 1 K07 HL088968-01
Amount: $129,600
Term: 2007 - 2012

Support for Studies of Neutrophil Function and Biochemistry
Principal Investigator: Daniel R. Ambruso, MD
Source: Bonfils Blood Center
Amount: $250,000/yr
Term: 1979 - 2008

Evaluation of Interactions between Forodesine and DNA Damaging Agents Using In Vitro Models of T Cell Acute Lymphoblastic Leukemia
Principal Investigator: Deborah A. Deryckere, PhD
Source: BioCryst Pharmaceuticals - PN200701-071-AMD01
Amount: $14,374/yr
Term: 2007 - 2008

Genetic Modifiers of von Willebrand Disease
Principal Investigator: Jorge Di Paola, MD
Source: NIH - R01 HL084086-01
Amount: $1,125,000/yr
Term: 2007 - 2012

Prevention of the Complications of Hemophilia Through Hemophilia Treatment Centers
Principal Investigator: Jorge Di Paola, MD
Source: CDC
Amount: $86,369/yr
Term: 2007 - 2008

Rural Comprehensive Care Hemophilia
Principal Investigator: Jorge Di Paola, MD
Source: Department of Human and Health Services, Iowa
Amount: $217,392/yr
Term: 2007 - 2008

U.S. Inhibitor Pilot Project
Principal Investigator: Jorge Di Paola, MD
Source: CDC
Amount: $52,392/yr
Term: 2007 - 2008

Comparative Growth Inhibition by Selectively Targeting PK-C zeta in Glioblastoma and Normal Astrocytes
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: American Cancer Society
Amount: $20,000/yr
Term: 2001 - present

Genomic and Proteomic Characterization of Diffuse Pontine Glioma
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: National Brain Tumor Foundation
Amount: $47,000/yr
Term: 2008 - 2009

Neuro-Oncology Fellowship to Study Oncogenic Pathways in Atypical Rhabdoid/Teratoid Tumors
Mentor: Nicholas K. Foreman, MB ChB
Source: American Brain Tumor Association
Amount: $75,000/yr
Term: 2008 - 2010

Neuro-Oncology Laboratory Support
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: ARTMA Foundation
Amount: $350,000,000
Term: 2000 - present

Neurotoxicity in Pediatric Cancer Survivors: Genetic Predictors, Structural Changes, and Improvements in Radiation Therapy Planning
Mentor: Nicholas K. Foreman, MB ChB
Source: Damon Runyon Cancer Research Foundation
Amount: $150,000/yr
Term: 2008 - 2011

Poetic BSG-HGA: Laboratory Correlates
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: Bristol-Myers Squibb - CA 225-296
Amount: $169,941/yr
Term: 2008 - 2009

Mechanisms of Protection of Varicella-Virus Infection against Glioblastoma
Principal Investigator: Adriana Weinberg, MD
Co-Investigator: Nicholas K. Foreman, MB ChB
Source: American Cancer Society
Amount: $50,000/yr
Term: 2007 - 2008

Development of a Next Generation Human Papillomavirus Vaccine
Co-Principal Investigators: Robert L. Garcea, MD, and Richard Schlegel, MD, PhD
Source: National Cancer Institute
Amount: $600,000/yr
Term: 2001 - present

Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Cancer Institute, NIH - 2R01 CA37667-21
Amount: $235,000/yr
Term: 2003 - 2008

Novel Therapeutic Vaccines for Acute and Persistent Papillomavirus Infections
Principal Investigator: Robert L. Garcea, MD
Source: Bill and Melinda Gates Foundation, Grand Challenges in Global Health - 37881
Amount: $3,540,000
Term: 2005 - 2010

Treatment of Children with Newly Diagnosed Low-Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
Principal Investigator: Timothy P. Garrington, MD
Source: Children’s Oncology Group
Amount: Per case reimbursement
Term: 2006 - present

Bone Marrow Transplant Database Redevelopment and Expansion Project
Principal Investigator: Roger H. Giller, MD
Source: Sean's Hope Foundation
Amount: $30,000/yr
Term: 2005 - 2007

Bone Marrow Transplant Database Redevelopment and Expansion Project
Principal Investigator: Roger H. Giller, MD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2005 - 2007

Famvir Pharmacokinetics in Children
Principal Investigator: Roger H. Giller, MD
Source: Novartis AG - G06893
Amount: $9,505/yr
Term: 2005 - 2008

A Phase III, Multicenter, Placebo-Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL
Principal Investigator: Roger H. Giller, MD
Source: Osiris
Amount: $29,262/yr
Term: 2007 - present

Retrospective Study of Ambisome Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant
Principal Investigator: Roger H. Giller, MD
Source: Astellas Pharmaceuticals - G06959
Amount: $14,650/yr
Term: 2005 - 2007

Multicenter Investigation of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation from HLA-Identical Donors for Sickle Cell Disease
Principal Investigator: Mark Walters, MD
Local Principal Investigator: Roger H. Giller, MD
Faculty: Rachelle Nuss, MD
Source: NIH - U01 - HL-068091
Amount: $44,400
Term: 2001 - 2006

Phase 2 Trial of Pentostatin for Treatment of Refractory Chronic GVH
Principal Investigator: David Jacobsen, MD
Co-Investigator: Roger H. Giller, MD
Source: Genzyme Corporation - G06962
Amount: $4,000/yr
Term: 2005 - 2007

Clinical Fellowship Award
Principal Investigator: Neil A. Goldenberg, MD, PhD
Faculty: Marilyn J. Manco-Johnson, MD
Source: National Hemophilia Foundation
Amount: $200,000
Term: 2004 - 2007

Clinical Fellowship Program
Mentor: Neil A. Goldenberg, MD, PhD
Source: National Hemophilia Foundation
Amount: $100,000/yr
Term: 2008 - 2010

Clinical Investigation in Pediatric Thrombosis
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: NHLBI, NIH - 1 K23 HL084055-01A1
Amount: $148,520/yr
Term: 2007 - 2012

Early Career Investigator Award: Use of a Global Assay and Comparative Proteomics in Hemophilia and von Willebrand Disease
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: Bayer Healthcare Pharmaceuticals Corporation - 200703-233
Amount: $100,000/yr
Term: 2007 - 2009

Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children (the Kids-DOTT Trial)
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: Eisai, Inc.
Amount: $108,671/yr
Term: 2009 - 2013

Scholar Award in Clinical/Translational Research
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: ASH
Amount: $150,000
Term: 2005 - 2007

Advancing Development and Support of the Pediatric Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: Alex's Lemonade Stand
Amount: $247,000/yr
Term: 2007 - 2009

Development of Noninvasive Methods for Analysis of Tumor Progression Using a Pre-Clinical Model of Pediatric Acute Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: American Cancer Society
Amount: $20,000/yr
Term: 2006 - 2008

Development of Noninvasive Methods for Analysis of Tumor Progression Using a Pre-Clinical Model of Pediatric Acute Leukemia
Principal Investigator: Lia Gore, MD
Source: American Cancer Society
Amount: $100,000/yr
Term: 2006 - 2008

Evaluation of the Anti-Tumor Activity of SAHA Administered in Combination with 5-Azacytidine Using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Source: Merck & Co., Inc. - LKR30891
Amount: $70,064/yr
Term: 2006 - 2010

Evaluation of the Anti-Tumor Activity of Vorinostat Administered in Combination with 5-Azacytidine Using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Merck & Co., Inc. - LKR30891
Amount: $55,584/yr
Term: 2008 - 2011

Expanding Access to New Agents for Cancer Treatment in Children
Principal Investigator: Lia Gore, MD
Source: Alex's Lemonade Stand
Amount: $100,000/yr
Term: 2006 - 2008

Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: TCH Research Institute
Amount: $214,000/yr
Term: 2004 - 2007

Identification of Molecular, Biochemical, and Phenotypic Differences in Cells Expressing PAX3-FKHR and PAX7-FKHR Fusion Proteins
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Bear Necessities Pediatric Cancer Foundation - PN200604-101
Amount: $40,000
Term: 2006 - 2007

Identification of Molecular, Biochemical, and Phenotypic Differences in Cells Expressing PAX3-FKHR and PAX7-FKHR Fusion Proteins
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Milheim Foundation - 2006-05
Amount: $7,672/yr
Term: 2006 - 2007

An International, Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin -5 Flurouracil (TCF) vs. Cisplatin -5 Flurouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Principal Investigator: Lia Gore, MD
Source: Sanofi-aventis U.S.
Amount: $16,483/yr
Term: 2007 - 2008

In Vitro and In Vivo Characterization of the Histone Deacetylase Inhibitors SAHA and MS-275 Alone and in Combination with Other Agents in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $26,500
Term: 2005 - 2006

Molecular Differences in Rhabdomyosarcomas with Alternative Fusion Proteins
Principal Investigator: Lia Gore, MD
Source: Milheim Foundation
Amount: $9,004
Term: 2006 - 2007

A Multicenter, Open-Label, Phase I Study of Single Agent R7112 Administered Orally in Patients with Advanced Malignancies, Except All Forms of Leukemia
Principal Investigator: Lia Gore, MD
Source: Hoffman La-Roche, Inc.
Amount: $757,666/yr
Term: 2008 - 2011

A Multicenter, Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDx5 Every Other Week in Pediatric Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: The Sunshine Project
Amount: $44,419/yr
Term: 2008 - present

Multiple Ascending Dose (MAD), Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: Hoffman La-Roche, Inc.
Amount: $130,038/yr
Term: 2007 - present

Novel Agents in the Therapy of Refractory Pediatric Brain Tumors
Principal Investigator: Lia Gore, MD
Source: Morgan Adams Foundation
Amount: $50,000/yr
Term: 2008 - present

An Open-Label, Phase I Study of RHUMAB IGRF in Patients with Advanced Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Principal Investigator: Lia Gore, MD
Source: Genentech BioOncology
Amount: $876,895/yr
Term: 2007 - present

An Open-Label Study to Assess the Pharmacokinetics of Leukovorin in Patients Receiving High-Dose Methotrexate, With or Without Voraxaze Treatment
Principal Investigator: Lia Gore, MD
Source: Protherics, Inc.
Amount: $8,100/yr
Term: 2008 - present

A Phase I, Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children with Relapsed or Refractory Acute Leukemias
Principal Investigator: Lia Gore, MD
Source: Genzyme Corporation
Amount: $14,342/yr
Term: 2007 - present

A Phase I, First-In-Human, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharamcodynamics of AMG 102 in Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: Amgen Research
Amount: $656,190/yr
Term: 2007 - present

A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients with Refractory Solid Malignancies
Principal Investigator: Lia Gore, MD
Source: AstraZeneca
Amount: $700,960/yr
Term: 2008 - present

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Azacitidine and Valproic Acid in Combination in Pediatric Patients with Advanced Malignancies
Principal Investigator: Lia Gore, MD
Source: Celgene Corporation
Amount: $32,071/yr
Term: 2008 - present

A Phase I Study of ErbituxTM(Cetuximab) in Pediatric Subjects with Refractory Solid Tumors: Characterization of Serum Pharmacokinetics, Safety, and Efficacy Following Single Doses and Repeated Weekly Administration when Combined with Irinotecan
Co-Principal Investigator: Lia Gore, MD
Source: Bristol-Myers Squibb Company
Amount: $259,626/yr
Term: 2005 - 2008

A Phase I Study of Liposomal Annamycin in Children and Young Adults with Refractory or Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Principal Investigator: Lia Gore, MD
Source: Callisto Pharmaceuticals, Inc.
Amount: $77,969/yr
Term: 2006 - present

A Phase I Study of TST10088 in Patients with Advanced Incurable Solid Tumors
Co-Principal Investigator: Lia Gore, MD
Source: Twinstrand Therapeutics
Amount: $351,875/yr
Term: 2005 - present

A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood
Principal Investigator: Lia Gore, MD
Source: Cephalon, Inc.
Amount: $10,777/yr
Term: 2008 - present

A Phase II, Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients with Previously-Treated Advanced or Metastatic Soft Tissue and Ewing’s Sarcoma/PNET
Principal Investigator: Lia Gore, MD
Source: ImClone Systems, Inc.
Amount: $18,492/yr
Term: 2008 - present

A Phase II Study of the Safety and Efficacy of Nimotuzumab in Pediatric Patients with Recurring Diffuse Brain Stem Glioma
Principal Investigator: Lia Gore, MD
Source: YM BioSciences, Inc.
Amount: $44,937/yr
Term: 2007 - present

Pre-Clinical Characterization of Histone Deacetylase Inhibitor Anti-Tumor Activity Using In Vitro and In Vivo Models of Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Cancer League of Colorado - 0503-087
Amount: $4,497/yr
Term: 2005 - 2007

Pre-Clinical Evaluation of Vandetanib in Pediatric Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Margaret Macy, MD
Source: For Julie Foundation Grant
Amount: $25,000/yr
Term: 2008 - 2010

Translational Research Project: Metabolic Markers of HDACI-Mediated Therapeutic Efficacy in Acute Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Leukemia and Lymphoma Society
Amount: $180,018/yr
Term: 2008 - 2011

K12 Clinical Oncology Scholars Award
Principal Investigator: Madeleine Kane, MD, PhD
Co-Investigator: Lia Gore, MD
Source: NIH - CA86913
Amount: $871,500
Term: 2001 - 2008

Phase I Drug Development Program
Co-Principal Investigator: Gail S. Eckhardt, MD
Co-Investigator: Lia Gore, MD
Source: National Cancer Institute, NIH - 5U01 CA099176-03
Amount: $1,622,852
Term: 2003 - 2008

Development of a Diagnostic FISH Assay for Mer Cytogenetic Abnormalities in Lymphoblastic Leukemia and Lymphoma
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $17,391
Term: 2006

Inhibition of Mer Tyrosine Kinase as a Novel Treatment for ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Milheim Foundation for Cancer Research
Amount: $13,636/yr
Term: 2006 - 2007

The Mer Oncogene and Merstatin: A Novel High-Impact Therapeutic Target
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $100,000
Term: 2005 - 2006

Mer Receptor Tyrosine Kinase Mutational Analysis in Pediatric ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: St. Baldrick’s Foundation
Amount: $18,600/yr
Term: 2006 - 2007

Mer Tyrosine Kinase as a Cooperative Oncogene in Leukemogenesis
Principal Investigator: Douglas K. Graham, MD, PhD
Source: G&P Foundation for Cancer Research - 30
Amount: $68,182/yr
Term: 2007 - 2010

The Mer Tyrosine Kinase as a Potential Therapeutic Target in Lymphoblastic Leukemias
Principal Investigator: Douglas K. Graham MD, PhD
Source: Cancer League of Colorado - 63066647
Amount: $30,000
Term: 2005 - 2006

A Novel Biologically Targeted Agent for the Treatment of Non-Small Cell Lung Cancer
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Colorado Bioscience Discovery Grant
Amount: $174,800/yr
Term: 2007 - 2008

Novel Biologically Targeted Therapy Against the Mer Receptor Tyrosine Kinase in the Treatment of Pediatric ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Damon Runyon Cancer Research Foundation - CI-39-07
Amount: $150,000/yr
Term: 2007 - 2010

Oncogenic Potential of Mer in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: National Childhood Cancer Foundation
Amount: $100,000
Term: 2005 - 2006

Soluble Mer Receptor Tyrosine Kinase as a Novel Therapeutic Agent for Pediatric T Cell Acute Lymphoblastic Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: American Cancer Society Institutional Research Grant
Amount: $20,000/yr
Term: 2006 - 2007

Target Validation of the Mer Receptor Tyrosine Kinase in the Treatment of Pediatric Astrocytomas
Principal Investigator: Douglas K. Graham, MD, PhD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008

Transforming Potential of the Mer Receptor Tyrosine Kinase in E2A-PBX1 Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Cure Search - 200709-061
Amount: $30,000/yr
Term: 2006 - 2008

The Use of Merstatin in the Treatment of Thrombosis
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $62,000
Term: 2006

Analysis of MerTK Contribution to Initiation of Leukemogenesis
Principal Investigator: Luis Brandao, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2008 - 2009

Effect of Overexpression of the Receptor Tyrosine Kinase Mer in a Transgenic Mouse Model
Principal Investigator: Dana Salzberg, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Research Scholar Award, TCH Research Institute
Amount: $55,000
Term: 2004 - 2006

J. Patrick Barnes Grants for Nursing Research and Evidence-Based Practice Projects
Principal Investigator: Molly Hemenway, ND, RN, AC/CPNP
Source: The DAISY Foundation
Amount: $2,500/yr
Term: 2007 - 2009

Best Pharmaceuticals for Children Award
Principal Investigator: Stephen P. Hunger, MD
Source: Children’s Oncology Group - 2 U10 CA98543-Reaman
Amount: $11,662/yr
Term: 2008 - 2009

Clinical Trials Core
Principal Investigator and Co-Chair: Stephen P. Hunger, MD
Source: Pediatric Cancer Foundation Sunshine Project and H. Lee Moffitt Cancer Center and Research Institute
Amount: $12,780/yr
Term: 2006 - 2009

COG ALL Committee
Principal Investigator and Chair: Stephen P. Hunger, MD
Source: Children’s Oncology Group - 2 U10 CA98543-Reaman
Amount: $46,650
Term: 2008 - 2009

COG ALL Committee
Principal Investigator and Vice Chair (Biology): Stephen P. Hunger, MD
Source: Children’s Oncology Group - U10 CA 98543-Reaman
Amount: $41,996/yr
Term: 2007 - 2008

Oncology Fellow Training Grant
Principal Investigators: Stephen P. Hunger, MD, and Douglas K. Graham, MD, PhD
Co-Investigator: Ralph R. Quinones, MD
Source: National Cancer Institute, NIH - CA 082086-05
Amount: $1,356,550
Term: 2005 - 2010

Specialized Center of Research in Targeted Therapies for Infant Leukemia
Principal Investigator: Stephen P. Hunger, MD
Source: Leukemia and Lymphoma Society
Amount: $5,000/yr
Term: 2007 - 2008

COG Specimen Banks Advance Pediatric Cancer
Principal Investigator: Greg Reaman, MD
Investigator: Stephen P. Hunger, MD
Source: National Cancer Institute, NIH - U24 CA 114766
Amount: $11,256/yr
Term: 2005 - 2010

Axl Receptor Tyrosine Kinase as a Therapeutic Target for Pediatric Myeloid Leukemia
Principal Investigator: Amy K. Keating, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Brent Ely Foundation - 2580861
Amount: $50,000/yr
Term: 2007 - 2009

Educational Support for Amy Keating
Principal Investigator: Amy K. Keating, MD
Source: Loan Repayment, NIH
Amount: $37,800/yr
Term: 2006 - present

Mer Receptor Tyrosine Kinase as a Biologic Marker and Therapeutic Target for Pediatric Leukemia
Principal Investigator: Amy K. Keating, MD
Source: Children’s Cancer Research Fund
Amount: $40,000/yr
Term: 2006 - 2007

Mer-Targeted Therapy for Human Acute Lymphoblastic Leukemia
Principal Investigator: Amy K. Keating, MD
Source: Amgen Oncology Institute Fellow
Amount: $40,000/yr
Term: 2006 - 2007

The Role of Mer and Axl Receptor Tyrosine Kinases in Pediatric Astrocytoma
Principal Investigator: Amy K. Keating, MD
Source: Loan Repayment Program, NIH
Amount: $34,000/yr
Term: 2008 - 2009

The Role of Mer and Axl Tyrosine Kinases in Pediatric Astrocytoma
Principal Investigator: Amy K. Keating, MD
Source: St. Baldrick’s Foundation
Amount: $110,000/yr
Term: 2008 - 2011

The Role of Mer and Axl Tyrosine Kinases in Non-Small Cell Lung Cancer
Principal Investigator: Rachel Linger, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Lung Cancer Research Foundation
Amount: $50,000/yr
Term: 2008 - 2009

The Role of Mer and Axl Tyrosine Kinases in Non-Small Cell Lung Cancer
Principal Investigator: Rachel Linger, MD
Mentor: Douglas K. Graham, MD, PhD
Source: NCI SPORE in Lung Cancer, UCD Cancer Center
Amount: $45,866/yr
Term: 2008 - 2009

The Preclinical Development of Vandetanib for Treatment of Pediatric Leukemia
Principal Investigator: Margaret E. Macy, MD
Source: Thorkildsen Research Fellowship
Amount: $35,000/yr
Term: 2008 - 2009

Creative Arts Therapist
Principal Investigator: Jennifer R. Madden, RN, MSN, CPNP
Source: Gabby Krause Foundation
Amount: $12,500/yr
Term: 2006 - 2009

COG Principal Investigator Salaries
Principal Investigator: Kelly W. Maloney, MD
Source: Children’s Oncology Group
Amount: $41,986/yr
Term: 2008 - 2009

COG Study Chair
Principal Investigator: Kelly W. Maloney, MD
Source: CureSearch
Amount: $27,990/yr
Term: 2008 - 2009

Psychosocial Outcomes of Pediatric Brain Tumors
Principal Investigator: Kelly W. Maloney, MD
Source: American Cancer Society
Amount: $72,000/yr
Term: 2003 - 2008

Clinical Fellowship Training Grant
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: National Hemophilia Foundation
Amount: $100,000/yr
Term: 2006 - 2008

Develop, Implement, and Ensure Comprehensive Hemophilia Evaluation and Management of Clinics for Federal Region VIII
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Maternal and Child Health Bureau, HRSA, HHS - 5 H30 MC00008-18-00
Amount: $344,000/yr
Term: 2007 - 2010

FDA Prelicensure Study of Haemocomplettan-P: Human Plasma-Derived Viral Inactivated Fibrinogen Concentrate
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: CSL Behring
Amount: $35,000/yr
Term: 2007 - 2010

Pharmaceutical Clinical Trials
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Bayer Pharmaceuticals
Amount: $389,576/yr
Term: 2007 - 2010

Pilot Project in Thrombophilia/Thrombosis Centers: Integrating Prevention Services for Persons with Bleeding and Clotting Disorders
Principal Investigator: Marilyn J. Manco-Johnson, MD
Consultant: Elizabeth Pounder, PA-C
Source: National Center on Birth Defects and Developmental Disabilities, CDC
Amount: $145,000/yr
Term: 2007 - 2012

Preventing Complications in Persons with Hemophilia
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: CDC
Amount: $87,000/yr
Term: 2006 - 2009

Prevention of the Complications of Hemophilia through Hemophilia Treatment Centers
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Boehringer Ingelheim
Amount: $300,000/yr
Term: 2006 - 2011

Provide Education, Community Outreach, and Direct Patient Care for Hemophilia and Related Bleeding Disorders
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: State of Colorado
Amount: $212,000/yr
Term: 2007 - 2010

SPINART: Adult Prophylaxis Study
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Bayer Healthcare Pharmaceuticals
Amount: $137,267
Term: 2008 - 2011

Program Project Grant for the Molecular and Clinical Biology of von Willebrand Disease
Principal Investigator: Robert Montgomery, MD
Co-Investigator: Marilyn J. Manco-Johnson, MD
Source: NHLBI, NIH - PO 1 HL 081588-01
Amount: $10,000/yr
Term: 2007 - 2010

Effect of Nitric Oxide for Restoring Hemostatic and Inflammatory Balance in Sickle Cell Disease
Principal Investigator: Rachelle Nuss, MD
Source: INO Therapeutics
Amount: $54,350
Term: 2005 - 2007

A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Principal Investigator: Rachelle Nuss, MD
Source: INO Therapeutics
Amount: $96,736
Term: 2005 - 2009

Comprehensive Sickle Cell Centers Priapism
Principal Investigator: Kathryn Hassell, MD
Co-Investigator: Rachelle Nuss, MD
Source: NHLBI, NIH - PN 200701-190
Amount: $38,962/yr
Term: 2007 - 2008

Extension Trial of an Oral Chelator ICL-670
Principal Investigator: Kathryn Hassell, MD
Investigator: Rachelle Nuss, MD
Source: Novartis AG
Amount: $119,690/yr
Term: 2005 - 2009

A Phase I/II Trial of Sildenafil for Sickle Cell-Associated Pulmonary Hypertension Clinical Trial
Principal Investigator: David Badesch, MD
Sub-Investigators: Kathryn Hassell, MD, and Rachelle Nuss, MD
Source: NHLBI, NIH - HB06-06
Amount: $217,917/yr
Term: 2006 - 2010

Identification of Drug Targets in AML Using a shRNA Library and Microarray Technology
Principal Investigator: Christopher Porter, MD
Source: St. Baldrick's Foundation
Amount: $7,500/yr
Term: 2007 - 2008

Impairing HPRT Function Improves the Efficacy of Treatment of Leukemia with 6-Thioguanine
Principal Investigator: Christopher Porter, MD
Source: UCD Cancer Center - CA103680-04
Amount: $20,000/yr
Term: 2007 - 2008

Impairment of Checkpoint Activation by the Oncogene E2a-Hlf Contributes to Leukemogenesis
Principal Investigator: Christopher Porter, MD
Source: W. M. Thorkildsen Research Fellowship
Amount: $25,000/yr
Term: 2005 - 2006

Modeling Treatment-Related Acute Myelogenous Leukemia
Principal Investigator: Christopher Porter, MD
Source: Brent Eley/Brian Hicks Research Award
Amount: $100,000/yr
Term: 2005 - 2007

Modeling Treatment-Related Acute Myelogenous Leukemia
Principal Investigator: Christopher Porter, MD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2005 - 2006

Paul Calabresi Clinical Oncology Scholars Award
Principal Investigator: Christopher Porter, MD
Source: UCD Cancer Center
Amount: $150,000/yr
Term: 2008 - 2013

A Pilot Study to Determine the Frequency and Significance of BCL-6 Expression and Mutation in Post-Transplantation Lymphoproliferative Disorder in Children
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Investigator: Christopher Porter, MD
Co-Investigator: Edythe A. Albano, MD
Source: Pediatric General Clinical Research Center, NCRR, NIH - M01 RR00069
Amount: $10,000/yr
Term: 2003 - 2006

National Cord Blood Bank Inventory Effort
Principal Investigator: Brian Freed, PhD
Co-Investigator: Ralph R. Quinones, MD
Source: HRSA, HHS
s Amount: $1,000,000/yr
Term: 2006 - 2016

An Animal Model of TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: NHLBI, NIH - R0-1 HL-59355-05
Amount: $200,000/yr
Term: 2003 - 2008

The Role of Human Antibodies in TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: Pall Corporation
Amount $2,100
Term: 2007

The Role of Mirasol in Inhibiting the Accumulation of Pro-Inflammatory Lipids in Stored Blood and Platelets Concentrates
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: Navigant
Amount: $81,671
Term: 2008

Role of the White Cell in Sickle Cell Disease
Principal Investigator: Christopher C. Silliman, MD, PhD
Investigator: Rachelle Nuss, MD
Source: Clinical Translational Research Center
Term: 2004 - 2008

Trauma Primes Cells
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: NIGMS, NIH - 2 P50 GM-49222
Amount $182,570/yr
Term: 2005 - 2010

Trauma Primes Cells (Project II): The Role of Neutral Lipophilic Compounds from Stored Blood in Pulmonary Endothelial Activation
Principal Investigator: Anirban Banejee, PhD
Co-Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institute of General Medical Sciences, NIH - 2 P50 GM-4922
Amount: $239,000/yr
Term: 2005 - 2010

DNA Methylation in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: Alex’s Lemonade Stand
Amount: $30,000/yr
Term: 2007 - 2008

Microrna Function in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: NINDS, NIH - KO8
Amount: $772,912/yr
Term: 2008 - 2013

Microrna Function in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: Bear Necessities Children’s Cancer Fund
Amount: $40,000/yr
Term: 2007 - 2008

Lymphotropic Polyomavirus Infection and Its Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Investigator: Michael Wang, MD
Source: Pediatric General Clinical Research Center, NCRR, NIH - M01 RR00069
Amount: $22,896/yr
Term: 2005 - 2006

Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: American Cancer Society, UCD Cancer Center Seed Grant
Amount: $20,000/yr
Term: 2005 - 2006

Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: St. Baldrick's Foundation
Amount: $5,000/yr
Term: 2006 - 2007

Mechanisms in Polyoma and Papillomavirus Assembly
Principal Investigator: Michael Wang, MD
Source: National Cancer Institute - 5 R01 CA 037667-23
Amount: $112,125/yr
Term: 2008 - 2009

Polyomavirus Infection and Human Malignancy
Principal Investigator: Michael Wang, MD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2008 - 2009

Polyomavirus Infection: Potential Role in Childhood Cancer
Principal Investigator: Michael Wang, MD
Source: St. Baldrick's Foundation
Amount: $49,320/yr
Term: 2008 - 2009

An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2005

An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2005

A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003-2005

Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - CA8208601
Amount: $999,879
Term: 2000-2005

Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - 2R01 CA37667-21
Amount: $235,000/yr
Term: 2003-2008

Development of a Next Generation Human Papillomavirus Vaccine
Co-Principal Investigators: Robert L. Garcea, MD, and Richard Schlegel, MD, PhD
Source: National Cancer Institute
Amount: $600,000/yr (current funding for GMP Production)
Term: 2001-present

PCR Analysis of Tumor and Normal DNA
Principal Investigator: Richard L. Garcea, MD
Source: National Cancer Institute - 40054-NV
Amount: $22,000
Term: 2004-2005

Novel Therapeutic Vaccines for Acute and Persistent Papillomavirus Infections
Principal Investigator: Richard L. Garcea, MD
Source: Bill and Melinda Gates Foundation, Grand Challenges in Global Health - 37881
Amount: $3,540,000
Term: 2005-2010

Postgraduate Training in Pediatric Oncology
Principal Investigator: Richard L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - T32-CA82086-05
Amount: $231,396/yr
Term: 2000-2005

MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute, K08 Award (Mentored Clinical Scientist Development Award) - CA85276-03
Amount: $662,500
Term: 2000-2005

American Society of Hematology Scholar Award in Clinical/Translational Research
Principal Investigator: Neil Goldenberg, MD
Source: CU Foundation - Project 2580553
Amount: $150,000
Term: 2005-present

Hemophilia and Thrombosis Research Society Thrombosis Studies Aware
Principal Investigator: Neil Goldenberg, MD
Source: CU Foundation - Program 37391
Amount: $35,000
Term: 2005

National Hemophilia Foundation Clinical Fellowship Award
Principal Investigator: Neil Goldenberg, MD
Faculty: Marilyn Manco-Johnson, MD
Source: UCD Office of Grants and Contracts - Project 200405-093
Amount: $200,000
Term: 2004-2007

K12 Clinical Oncology Scholars Award
Principal Investigator: Lia Gore, MD,
Source: National Institutes of Health - CA86913
Amount: $525,000
Term: 2001-2006

Phase I Drug Development Program
Co-Principal Investigators: Lia Gore, MD, and Gail S. Eckhardt, MD
Source: National Institutes of Health, National Cancer Institute -5U01 CA099176-03
Amount: $1,622,852
Term: 2003-2008

In Vitro and In Vivo Characterization of the Histone Deacetylase Inhibitors SAHA and MS-275 Alone, and in Combination with Other Agents in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $26,500
Term: 2005-2006

Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: The Children's Hospital Research Institute
Amount: $214,000/yr
Term: 2004-2008

Evaluation of the Anti-Tumor Activity of SAHA Administered in Combination with 5-Azacytidine using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Source: Merck & Co, Inc.
Amount: $60,062
Term: 2005-2006

The Mer Tyrosine Kinase as a Potential Therapeutic Target in Lymphoblastic Leukemias
Principal Investigator: Douglas K. Graham MD, PhD
Source: Cancer League of Colorado - 63066647
Amount: $30,000
Term: 2005-2006

The Mer Oncogene and Merstatin: a Novel High Impact Therapeutic Target
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $100,000
Term: 2005-2006

An Animal Model of TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institutes of Health - HL-59355-05
Amount: $2,402,388
Term: 1999-2007

Project II: The Role of Neutral Lipophilic Compounds from Stored Blood in Pulmonary Endothelial Activation
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institutes of Health, National Institute General Medical Sciences
Amount: $1,615,579
Term: 2005-2010

Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: American Cancer Society, University of Colorado Cancer Center Seed Grant
Amount: $20,000
Term: 2005

Lymphotropic Polyomavirus Infection and Its Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: National Institutes of Health, National Centers for Research Resources, UCD Pediatric Clinical Translational Research Center, General Clinical Research Centers Program - M01 RR00069
Amount: $22,896/yr
Term: 2005-2006

An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present

An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present

A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003-present

Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer, Inc.
Amount: $2,000/yr
Term: 2001-2012

Comparative Growth Inhibition by Selectively Targeting PK-C zeta in Glioblastoma and Normal Astrocytes.
Principal Investigator: Nicholas K. Foreman, MD, ChB
Source: American Cancer Society
Amount: $20,000/yr
Term: 2001-present

Microbial Pathogenesis and Host Responses to Infection
Principal Investigator: Randall K. Holmes, MD, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - CAI 07537
Amount: $380,515
Term: 1999-2004

Predoctoral Training Program in Molecular Biology
Principal Investigator: Charles McHenry, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - GM08730-01
Amount: $88,328
Term: 1999-2004

Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - CA8208601
Amount: $999,879
Term: 2000-2005

MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute, K08 Award (Mentored Clinical Scientist Development Award) - CA85276-03
Amount: $662,500
Term: 2000-2005

Children's Oncology Group
Principal Investigator: Roger Giller, MD
Source: University of Colorado, Department of Pediatrics
Amount: $175,640
Term: 1980-2003

Multicenter Investigation of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation from HLA-Identical Donors for Sickle Cell Disease
Principal Investigator: Roger Giller, MD
Faculty: Rachelle Nuss, MD
Source: National Institutes of Health U01 - HL-068091
Amount: $44,400
Term: 2001-2006

K12 Clinical Oncology Scholars Award
Principal Investigator: Lia Gore, MD
Source: National Institutes of Health - CA86913
Amount: $871,500
Term: 2001-2008

Orphan Drug Act
Principal Investigator: Lia Gore, MD
Source: US Food and Drug Administration
Amount: $136,862
Term: 2002-2003

Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: Morgan Adams Memorial Neuro-Oncology Research Fund
Amount: $50,000/yr
Term: 2002-present

Brent Eley Research Fellow
Principal Investigator: Douglas K. Graham, MD, PhD
Source: The Children's Hospital Research Institute Scholar Award
Term: 2001-2003

Expression of Mer in Pediatric Leukemia Patient Samples
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Children's Cancer Research Fund
Term: 2002-2003

Butterfly Program
Principal Investigator: Brian S. Greffe, MD
Source: Children's Hospice International Grant
Amount: $100,000
Term: 2002-2004

K08 B Cell Expansion After Dendritic Cell Immunization
Principal Investigator: Michael B. Jordan, MD
Source: National Institutes of Health - K08 AI50802
Amount: $360,000
Term: 2002-2005

An Animal Model of Hemophagocytic Lymphohistiocytosis
Principal Investigator: Michael B. Jordan, MD
Source: The Histiocytosis Association of America
Amount: $60,000
Term: 2002-2004

Suicide Liposomes for Treatment of Immune-Mediated Anemia in Dogs
Co-Principal Investigators: Michael B. Jordan, MD, and Steven Dow, DVM, PhD
Source: The Morris Foundation
Amount: $120,000
Term: 2002-2005

Abnormal Hemoglobin Testing and Counseling Services
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Wyoming Department of Health
Amount: $4,880
Term: 2001-2003

Sickle Cell Center Contract for Newborn Screening Follow-Up
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Colorado Department of Health
Amount: $175,164
Term: 2001-2003

Teaching and Interpretation of Hemoglobin Electrophoresis
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: University of Colorado Hospital Laboratory
Amount: $10,000
Term: 2001-2003

Early Hearing Detection and Intervention: Tracking, Research and Integration with Other Newborn Screening Programs
Principal Investigator: Peter A. Lane, MD
Faculty: Rachelle Nuss, MD
Source: Centers for Disease Control and Prevention - 02-00556
Amount: $115,000
Term: 2001-2004

Develop, Implement and Ensure Comprehensive Hemophilia Evaluation and Management of Clinics for Federal Region VIII
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau - MC00008-01
Amount: $499,684
Term: 2001-2003

Integrating Prevention Services for Persons with Bleed and Clotting Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU8200552-01
Amount: $184,441
Term: 2001-2003

Preventing Complications in Persons with Hemophilia (Mountain States Regional Hemophilia Center)
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU813109-06
Amount: $323,778
Term: 2001-2003

Prevention of Joint Disease in Preschool Children with Hemophilia
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU812106-07
Amount: $211,114
Term: 2001-2003

Provide Education, Community Outreach and Direct Patient Care for Hemophilia and Related Bleeding Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: State of Colorado
Amount: $231,625
Term: 2001-2003

The Acute Chest Syndrome in Sickle Cell Anemia: The Role of the Neutrophil
Co-Principal Investigators:Rachelle Nuss, MD, and Christopher Silliman, MD, PhD
Source: Pediatric General Clinical Research Center - Pilot
Amount: $90,000
Term: 2002-2003

An Animal Model of TRALI
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health - HL-59355-05
Amount: $2,402,388
Term: 1999-2007

Project IX: Lipid Chemistry CORE, PO-A: The Role of Lipids Generated During Blood Storage in Trauma-Induced Multiple Organ Failure
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health - GM49222-12
Amount: $3,346,299
Term: 2001-2004

Head CT in the Evaluation of 1st Afebrile Seizures
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, Louis C. Hampers, MD, MBA, Carol Okada, MD, and Rebecca Fastle, MD
Term: 2000-2004

Postreduction Management of Intussusception
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, and Shayne Bland, MSc
Term: 2000-2002

Emergency Medical Services for Children Partnership Grant
Principal Investigator: F. Keith Battan, MD
Source: US Department of Health and Human Services, Maternal and Child Health Bureau -
FLAEMS01-00250
Amount: $122,000
Term: 2000-2001

L.O.C.O. (Latinos Overcoming Cultural Obstacles) "Needs Assessment for The Children's Hospital"
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001

The Truth about Language Barriers
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Stephen Federico, MD
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001-ongoing

Jungle Mobile: A Mobile Injury Prevention Project for Children
Principal Investigator: Kathryn D. Emery, MD
Co-Investigators: Allison Hawkes, MD, MS, Theresa Rapstine, RN, and Victoria Cassenbaugh, RN
Term: 1998-ongoing

A Screening Tool for the Detection of Child Abuse in the Emergency Department Setting
Joint Project with the Child Advocacy Protection Team

Principal Investigator: Kathryn D. Emery, MD
Term: 2001

Seat Belt and Car Safety Seat Use in SUVs
Primary Investigator: Kathryn D. Emery, MD
Co-Investigators: Lisa Hardin Van Bramer, MD, and Kevin Raines, MD
Source: National Highway Traffic Safety Administration - STNH22-01-H-05-257
Amount: $350,000
Term: 2001-2003

Childhood Injury Prevention Concerns of Migrant and Seasonal Farm Workers in Weld County
Principle Investigator: Kathryn D. Emery, MD
Co-Investigator: S. Glenn Faries, MD
Source: Colorado Injury Control Research Center
Amount: $15,000
Term: 2002-2003

Domestic Violence Policies in Pediatric Emergency Departments
Principle Investigator: Kathryn D. Emery, MD
Co-Investigators: Sheila Sullivan, MD, Andrew P. Sirotnak, MD, and Stephanie Stronks-Knapp, MD
Term: 2002-ongoing

Development of an Injury-Free Coalition for Kids
Principal Investigator: S. Glenn Faries, MD
Co-Investigator: Kathryn D. Emery, MD
Term: 2001-ongoing

Resident Education in the Emergency Department
Principal Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Need for Atropine for Emergent Pediatric Intubations
Principal Investigator: Rebecca Fastle, MD
Co-Investigator: Mark G. Roback, MD
Term: 1999-ongoing

Resuscitation Teaching at Primary Care Centers
Principal Investigator: Margaret Ferguson, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-ongoing

Utility of Anaerobic Blood Cultures in a Pediatric Emergency Department
Principal Investigator: Stephen Freedman, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2003

PEM Collaborative Research Committee, Cerebral Edema and DKA
Principal Investigator: Nicole Glaser, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-2001

Comparison of Oral Prednisone vs. Dexamethasone in Pediatric Asthma
Principal Investigator: Richard A. Greenberg, MD
Co-Investigators: Genie E. Roosevelt, MD, MPH, and Gwendolyn S. Kerby, MD
Term: 2002-ongoing

Peak Flow vs. Spirometry in Acute Asthma
Principal Investigator: David Gutglass, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 1997-ongoing

A.C.C.E.S.S. for Latinos: After-Hours Call Center and Extended Spanish Service
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: Lauren Clark, PhD, RN, and Stephen Berman, MD
Term: 2001-2002

The Impact of Interpreters on Resource Utilization in a Pediatric Emergency Department
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Jennifer McNulty, MD
Term: 1999-2002

Physician-Based Practice Pattern Variations in the Management of AGE
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Elizabeth Powell, MD, MPH
Term: 2001-ongoing

Practice Variation in the Management of Croup
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 1999-2002

Regional After-Hours Urgent Care Provided by a Tertiary Children's Hospital
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 2001-2002

Booster Seat Project
Principal Investigator: Lisa Hardin Van Bramer, MD
Co-Investigator: Kathryn D. Emery, MD
Source: Emergency Medical Services and Kiwanis Pediatric Trauma Institute
Amount: $18,000
Term: 2001-2002

Association of Influenza with Bacterial Tracheitis
Principal Investigator: Ron L. Kaplan, MD
Co-Investigators: Mark G. Roback, MD, and Peggy Kelly, MD
Term: 2002-ongoing

Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Patients Birth to 48 Months Old with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: S. Glenn Faries, MD
Term: 2001-2002

Effect of Ondansetron on Ketamine Sedation-Associated Vomiting
Principal Investigator: William T. Langston, MD
Co-Investigators: Joseph E. Wathen, MD, and Mark G. Roback, MD
Source: The Children's Hospital Research Institute
Amount: $5,000
Term: 2002-ongoing

Effect of Medical Spanish Classes on Satisfaction of Hispanic Patients in Pediatric Emergency Department
Principal Investigator: Suzanne Mazor, MD
Co-Investigators: Vidya Chande, MD, Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 2000-2002

Interpretation of Traumatic Lumbar Punctures: Who Can Go Home?
Principal Investigator: Suzan Mazor, MD
Co-Investigators: Jennifer McNulty, MD, and Genie E. Roosevelt, MD, MPH
Term: 2001-ongoing

How Is Emergency Department Decision-Making Affected by the Existence of Reliable Follow-Up?
Principal Investigator: Jennifer McNulty, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 1999-2001

Decision Rules for Obtaining Radiographs in Pediatric Knee Injuries
Principal Investigator: Brian Moore, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Kathryn Emery, MD
Term: 1998-ongoing

Indications for Knee Radiographs in Pediatric Patients with Acute Knee Injuries/Validation of a Clinical Decision Rule
Principal Investigator: Brian Moore, MD
Co-Investigators: Carol Turner, MD, and Kathryn D. Emery, MD
Term: 2000-ongoing

Correlation of Hemolysis with Facticous Hyperkalemia
Principal Investigator: Heather Owens, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Acute Complication of Type 1 Diabetes in Children
Primary Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Mark G. Roback, MD, and Joan P. Bothner, MD
Term: 2001-ongoing

Childhood Pedestrian Injuries
Primary Investigator: Arleta B. Rewers, MD, PhD
Term: 2002-ongoing

Femur Fractures and Associated Injuries
Principal Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Kathryn D. Emery, MD, and F. Keith Battan, MD
Term: 2000-ongoing

Are Chest X-Rays Required for all First-Time Wheezers?
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Mark E. Anderson, MD, and John D. Strain, MD
Term: 1998-ongoing

Comparison of the Efficacy and Safety of Sedation Drugs Used in a Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Joseph E. Wathen, MD, and Joan P. Bothner, MD
Term: 1999-ongoing

IV vs. IM Ketamine Sedation in the Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Joseph E. Wathen, MD
Source: The Children's Hospital Research Institute
Amount: $35,000
Term: 2000-ongoing

Pediatric Resuscitation Practice and Success Rate
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Rebecca Fastle, MD
Term: 2000-ongoing

Predictors of Which Patients will Benefit from Observations vs. Hospital Admission
Principal Investigator: Genie E. Roosevelt, MD, MPH
Co-Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Randomized, Double-Blind Study of Intravenous Fluids With and Without Dextrose in the Treatment of Dehydration in Pediatric Patients with Vomiting and Ketosis
Principal Investigator: Genie E. Roosevelt, MD, MPH
Term: 2002-ongoing

The Effect of Dehydration on the QT Interval of Healthy Children
Principal Investigator: Carl Shaw, MD
Co-Investigators: Joseph E. Wathen, MD, and Michael S. Schaffer, MD
Term: 2001

The Prevalence of Urinary Tract Infections in Febrile Children with AGE
Principal Investigator: Carl Shaw, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Use of Complementary Medicine in Pediatric Patients with Asthma
Principal Investigator: Alison Siegel Tothy, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2002

Associations between Insurance Type and Pediatric Admission Rate in Colorado, 1993-1999: Is Managed Care Fulfilling Its Promise?
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and James K. Todd, MD
Term: 2000-ongoing

Associations of Parental Depression and Child Health Outcomes
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Allison Kempe, MD, John Steiner, MD, David Price, MD, and David Magid, MD
Term: 2002-ongoing

Comparison of the Longitudinal Marginal Cost, Morbidity and Mortality of Inflicted and Unintentional Head Injuries in Young Children in a Nationwide Sample of Children's Hospitals
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Costs of Childhood Physical Abuse: Comparing Inflicted and Unintentional Head Injuries in Colorado Inpatients Under Three Years Old
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Epidemiology of Pediatric Psychiatric Visits to US Emergency Departments, Based on the National Hospital Ambulatory Medical Care Survey 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Hospital-Level Predictors of Inefficiency Amongst Hospitalized Patients in New York State
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and Andrew Racine, MD, PhD
Term: 2000-ongoing

Management of Acute Gastroenteritis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Management of Bronchiolitis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1993-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Comparison of Fascia Iliaca Compartment Nerve Block to Traditional Systemic Analgesics for Femur Fractures in a Pediatric Emergency Department
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Glen Merritt, MD, Gaia Georgopoulos, MD, and F. Keith Battan, MD
Source: The Children's Hospital Research Institute
Amount: $17,594
Term: 2001-2004

Pediatric EKG Interpretation Accuracy by Pediatric Emergency Medicine Physicians
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Arleta Rewers, MD, PhD, Angela Yetman MD, and Michael Schaffer MD
Term: 2001-ongoing

A Randomized Trial of Telephonic vs. On-Site Language Interpretation in a Pediatric ED
Principal Investigator: Ethan S. Wiener, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing